Innovent Biologics closes Takeda partnership, completes HK$778m share issuance

Innovent Biologics Inc. announced the closing of its global strategic partnership with Takeda and a related share issuance on December 4, 2025. All precedent conditions for the License, Option and Collaboration Agreement and the Share Issuance Agreement have been fulfilled or waived.

Under the Share Issuance Agreement, Innovent allotted and issued 6,913,834 shares to a subscriber, representing approximately 0.40% of the company's issued share capital post-issuance. The gross proceeds from this issuance amounted to approximately HK$778 million, based on a subscription price of HK$112.56 per share, with net proceeds totaling approximately HK$777 million after deducting incidental expenses.

These Subscription Shares were issued under the General Mandate, which allows for the issuance, allotment, and dealing of up to 248,010,358 shares. Following this transaction, the company retains the ability to allot, issue, and deal with up to 186,096,524 additional shares under the General Mandate.